Circulating tumor cells in colorectal cancer patients

Torino, Francesco; Bonmassar, Enzo; Bonmassar, Laura; Vecchis, Liana De; Barnabei, Agnese; Zuppi, Cecilia; Capoluongo, Ettore; Aquino, Angelo

doi:10.1016/j.ctrv.2012.12.007

Cited by 50 publications

(40 citation statements)

References 157 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, as a noninvasive method, detection of CTCs is an alternative approach due to the invasive characteristics of surgical and/or biopsy specimens, dynamic molecular changes of tumor cells during the therapeutic process, and tumor heterogeneity [10], [11]. CTCs in peripheral blood are extremely rare, and the frequency is approximately 1 CTC per 10 6 to 10 7 peripheral blood mononuclear cells [12]. Thus, CTC research has been greatly limited by the isolation and detection of CTCs.…”

Section: Introductionmentioning

confidence: 99%

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

Zheng

Фан

Zhou

et al. 2017

Translational Oncology

View full text Add to dashboard Cite

PURPOSE: Gastric cancer studies indicated a potential correlation between circulating tumor cells (CTCs) in peripheral blood and tumor relapse/metastasis. The prevalence and significance of circulating tumor microemboli (CTM) in gastric cancer remain unknown. We investigated the prevalence and prognostic value of CTCs and CTM for progression-free survival (PFS) and overall survival (OS) in gastric cancer patients. METHODS:Eighty-one gastric cancer patients consented to provide 5 ml of peripheral blood before systematic therapy. CTCs and CTM were isolated using isolation by size of epithelial tumor cells and characterized by cytopathologists. For 41 stage IV gastric cancer patients, CTM was investigated as a potential biomarker to predict prognosis. RESULTS:CTCs were detected in 51 patients; the average count was 1.81. In clinical stage I, II, III, and IV patients, the average CTC counts were 1.40, 0.67, 1.24, and 2.71, respectively. CTM were detected in 3 of 33 clinical stage I to IIIb patients, at an average of 0.12 (0-2). CTM were detected in 13 of 53 clinical stage IIIc to IV patients, at an average of 1.26 (0-22). In stage IV patients, CTM positivity correlated with the CA125 level. PFS and OS in CTM-positive patients were significantly lower than in CTM-negative patients (P < .001). CTM positivity was an independent factor for determining the PFS (P = .016) and OS (P = .003) of stage IV patients in multivariate analysis. Using markers of the epithelial-mesenchymal transition, single CTCs were divided into three phenotypes including epithelial CTCs, biphenotypic epithelial/mesenchymal CTCs, and mesenchymal CTCs. For CTM, CK−/Vimentin+/CD45− and CK+/Vimentin+/CD45− phenotypes were observed, but the CK+/Vimentin−/CD45− CTM phenotype was not. CA125 was detected in gastric cancer cell lines BGC823 and MGC803. CONCLUSIONS: In stage IV patients, CTM positivity was correlated with serum CA125 level. CTM were an independent predictor of shorter PFS and OS in stage IV patients. Thus, CTM detection may be a useful tool to predict prognosis in stage IV patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

Zheng

Фан

Zhou

et al. 2017

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…It is very important to note that plastin3 expression was also detected in all patients with recurrent disease, and at a level higher than in the case of prerecurrence and of patients without recurrence [34]. The correlation between CTCs and prognosis in CRCs was stronger if CKs and multiple markers were used than for the one-marker assay [35].…”

Section: Colorectal Cancer (Crc)mentioning

confidence: 99%

Clinical studies monitoring circulating and disseminated tumor cells in gastrointestinal cancers

Eliasova

Kološtová

Kobierzycki

et al. 2014

Folia Histochem Cytobiol.

View full text Add to dashboard Cite

Abstract:Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are responsible for the development of metastatic disease, and may also hold the key to determining tailored therapies of advanced cancer disease. Our review summarizes the prognostic significance of the detection of CTCs and DTCs in various gastrointestinal cancers with an overview of their possible use as prognostic biomarkers. This could be used in the future as a starting point for new clinical trials focusing on the predictive potential of circulating and disseminated tumor cells. (Folia Histochemica et Cytobiologica 2013, Vol. 51, No. 4, 265-277) Key words: circulating tumor cells; gastrointestinal cancer; esophageal cancer; colorectal cancer; gastric cancer; plastin3; prognosis Abbreviations AFP -alpha fetoprotein; BM -bone marrow; CD -cluster of differentiation; CEA -carcinoembryonic antigen; CHT -chemotherapy; CI -confidence interval; CTC -circulating tumor cell; CRCcolorectal carcinoma; CVB -central venous blood; CK -cytokeratin; DAPI -4,6-diamidino-2-phenylindole; DFS -disease free survival; DTC -disseminated tumor cell; EpCAM -epithelial cell adhesion molecule; FISH -fluorescent in situ hybridization; 5-FU -5-fluorouracil; HCC -hepatocellular carcinoma; HR -hazard ratio; ISET -isolation by size of epithelial tumor; ITC -isolated tumor cells; MACS -magnetic activated cell sorting; MFS -metastasis free survival; MSP -methylation specific polymerase chain reaction; MVB -mesenteric venous blood; NA -not available; OS -overall survival; PB -peripheral blood; PFS -progression-free survival; qPCR -quantitative real-time polymerase chain reaction; RFA -radiofrequency ablation; RT -radiotherapy; RT-PCR -reverse transcription polymerase chain reaction; TGFb1 -transforming growth factor b1; TRC method -transcription reverse-transcription concerted method

show abstract

“…The Veridex CellSearch system (Veridex LLC, Raritan, NJ) utilizes magnetic beads coated by anti-EpCAM antibody to capture cells followed by the fluorescence staining to identify CTCs, defined as CK8/18/19+/DAPI+/CD45− cells [8]. However, EpCAM expression is dependent on the local microenvironment and is down-regulated in disseminated cells [9].…”

Section: Introductionmentioning

confidence: 99%

Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy

et al. 2017

View full text Add to dashboard Cite

BackgroundCirculating tumor cells (CTCs) detected in peripheral blood (PB) of cancer patients can be identified as isolated CTCs and circulating tumor microemboli (CTM). This study aimed to evaluate the prognostic value of CTM detection and CTC phenotype in advanced colorectal cancer (CRC) patients during chemotherapy.MethodsA size-based platform for CTC isolation was applied. PB samples (5 ml) from 98 advanced CRC patients during 2–6 cycles chemotherapy were collected for CTC detection, and CTC count was correlated to patient’s clinicopathological characteristics and clinical outcome. And CTC phenotype was measured by immunofluorescent staining and evaluate the predictive significance on survival in 32 CTCs-positive patients with advanced CRC.ResultsForty-eight of 98 patients were CTCs-positive, including 18 CTM-positive patients, and CTC detection was positively correlated with lymphatic invasion (P = 0.049), TNM stage (P = 0.023), and serum CEA level (P = 0.014). Moreover, Kaplan–Meier survival and Cox regression analyses revealed that the presence of CTCs was an independent factor for poor PFS and OS (P < 0.05) in advanced CRC patients during chemotherapy, and CTM-positive patients had shooter survival than isolated CTCs-positive patients (P < 0.05). Furthermore, patients with vimentin+ isolated CTCs/CTM had shorter PFS and OS compared with CK+ CTCs (P < 0.05).ConclusionsThis study provided evidence that the presence of CTCs was positively correlated with poor prognosis, and furthermore, CTM and vimentin+ CTCs predicted poorer survival, which indicated that CTM and vimentin+ CTCs detected by a sensitive platform could be used to improve prognostic value of CTCs in advanced CRC patients under treatment.

show abstract

Circulating tumor cells in colorectal cancer patients

Cited by 50 publications

References 157 publications

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

Detection of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer

Clinical studies monitoring circulating and disseminated tumor cells in gastrointestinal cancers

Circulating tumor microemboli (CTM) and vimentin+ circulating tumor cells (CTCs) detected by a size-based platform predict worse prognosis in advanced colorectal cancer patients during chemotherapy

Contact Info

Product

Resources

About